Category: Biotech

Fortress Biotech, Inc.Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024MIAMI, May 15, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical…
Read More…

Source: https://finance.yahoo.com/news/fortress-biotech-reports-first-quarter-201500284.html

Source: PowerUp / Shutterstock.com

MAIA Biotechnology (NYSEMKT:MAIA) just reported results for the first quarter of 2024.MAIA Biotechnology reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -39 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace…
Read More…

Source: https://investorplace.com/earning-results/2024/05/maia-stock-earnings-maia-biotechnology-for-q1-of-2024/?utm_source=financialcontent&utm_medium=quotes

The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and exhibits. From massive exhibition to jam-packed conference sessions, from groundbreaking product launches to cutting-edge startup showcase, from insightful panel discussions to valuable networking opportunities, and from fruitful business matchmaking sessions to noteworthy partnership announcements, the event has undeniably made a…
Read More…

Source: https://startupnews.fyi/2024/05/15/successful-conclusion-of-london-biotechnology-show-leaves-attendees-highly-satisfied/

AIIMS Delhi Microbiology, Life Sciences, Biotechnology JRF Job Opening – Applications Invited
ALL INDIA INSTITUTE OF MEDICAL SCIENCES NEW DELHI DEPARTMENT OF NMR
Advertisement for Junior Research Fellow Date of Advertisement: May 14, 2024
Applications are invited only for research project position as per the details given below, under Principal Investigator (Dr. Virendra Kumar), Department of NMR, All India Institute of Medical Sciences, New Delhi.
Title of project:…
Read More…

Source: https://www.biotecnika.org/2024/05/aiims-delhi-microbiology-life-sciences-biotechnology-jrf-job-opening-applications-invited/?amp

The makers of the world’s first phase two AI generated drug said the UAE can be at the heart of a new era in the fight against disease.The drug discovery process, traditionally known for its complexity and lengthy timelines, is undergoing a significant transformation with the rise of artificial intelligence.Historically, developing a new drug could take up to 12 years and had a success rate of less than 1 per cent. However, AI is set to change this, enhancing efficiency and reducing costs…
Read More…

Source: https://www.thenationalnews.com/news/uae/2024/05/14/ai-generated-drugs-can-lead-new-era-in-fight-against-disease-biotech-chief-says/

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. “Our team remains focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foselutoclax) against aflibercept,” said Anirvan Ghosh, Ph.D., chief executive…
Read More…

Source: https://www.globenewswire.com/news-release/2024/05/14/2881956/0/en/UNITY-Biotechnology-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Updates.html

On May 8, 2024, the U.S. Environmental Protection Agency (EPA), U.S. Department of Agriculture (USDA), and U.S. Food and Drug Administration (FDA) released a joint plan to identify areas of ambiguity, gaps, or uncertainty in their coordinated regulation of biotechnology products. Consistent with a directive issued by President Biden in September 2022, the agencies’ plan identifies specific issues that each has either recently addressed or will work to address to promote such products’…
Read More…

Source: https://www.jdsupra.com/legalnews/epa-usda-and-fda-to-clarify-overlapping-3605487/